{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:08:40Z","timestamp":1771351720304,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,7]]},"DOI":"10.7759\/cureus.61890","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T14:12:45Z","timestamp":1717769565000},"source":"Crossref","is-referenced-by-count":1,"title":["Breakthrough Pneumocystis jirovecii Pneumonia in an Allogeneic Hematopoietic Stem Cell Transplant Recipient"],"prefix":"10.7759","author":[{"given":"Tarek","family":"Zieneldien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1764375","article-title":"Pneumocystis jiroveci pneumonia: a review of management in human immunodeficiency virus (HIV) and non-HIV immunocompromised patients","volume":"13","author":"Ibrahim A","year":"2023","unstructured":"Ibrahim A, Chattaraj A, Iqbal Q, et al.. Pneumocystis jiroveci pneumonia: a review of management in human immunodeficiency virus (HIV) and non-HIV immunocompromised patients. Avicenna J Med. 2023, 13:23-34. 10.1055\/s-0043-1764375","journal-title":"Avicenna J Med"},{"key":"ref2","article-title":"Pneumocystis jirovecii pneumonia","author":"Truong J","year":"2024","unstructured":"Truong J, Ashurst JV. Pneumocystis jirovecii pneumonia. StatPearls. StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.880","article-title":"Evolving health effects of pneumocystis: one hundred years of progress in diagnosis and treatment","volume":"301","author":"Kovacs JA","year":"2009","unstructured":"Kovacs JA, Masur H. Evolving health effects of pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009, 301:2578-85. 10.1001\/jama.2009.880","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38618-3","article-title":"Risk factors and clinical characteristics of Pneumocystis jirovecii pneumonia in lung cancer","volume":"9","author":"Lee EH","year":"2019","unstructured":"Lee EH, Kim EY, Lee SH, et al.. Risk factors and clinical characteristics of Pneumocystis jirovecii pneumonia in lung cancer. Sci Rep. 2019, 9:2094. 10.1038\/s41598-019-38618-3","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019828","article-title":"Pneumocystis","volume":"4","author":"Gigliotti F","year":"2014","unstructured":"Gigliotti F, Limper AH, Wright T. Pneumocystis. Cold Spring Harb Perspect Med. 2014, 4:10.1101\/cshperspect.a019828","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1753425912436763","article-title":"Primary alveolar epithelial cell surface membrane microdomain function is required for Pneumocystis \u03b2-glucan-induced inflammatory responses","volume":"18","author":"Evans SE","year":"2012","unstructured":"Evans SE, Kottom TJ, Pagano RE, Limper AH. Primary alveolar epithelial cell surface membrane microdomain function is required for Pneumocystis \u03b2-glucan-induced inflammatory responses. Innate Immun. 2012, 18:709-16. 10.1177\/1753425912436763","journal-title":"Innate Immun"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4137\/CCRPM.S23324","article-title":"Pneumocystis pneumonia in human immunodeficiency virus-infected adults and adolescents: current concepts and future directions","volume":"9","author":"Tasaka S","year":"2015","unstructured":"Tasaka S. Pneumocystis pneumonia in human immunodeficiency virus-infected adults and adolescents: current concepts and future directions. Clin Med Insights Circ Respir Pulm Med. 2015, 9:19-28. 10.4137\/CCRPM.S23324","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.7329","article-title":"Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection","volume":"198","author":"Kanne JP","year":"2012","unstructured":"Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol. 2012, 198:W555-61. 10.2214\/AJR.11.7329","journal-title":"AJR Am J Roentgenol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra032588","article-title":"Pneumocystis pneumonia","volume":"350","author":"Thomas CF Jr","year":"2004","unstructured":"Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004, 350:2487-98. 10.1056\/NEJMra032588","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.1.183","article-title":"Salvage therapy with clindamycin\/primaquine for Pneumocystis carinii pneumonia","volume":"14","author":"Noskin GA","year":"1992","unstructured":"Noskin GA, Murphy RL, Black JR, Phair JP. Salvage therapy with clindamycin\/primaquine for Pneumocystis carinii pneumonia. Clin Infect Dis. 1992, 14:183-8. 10.1093\/clinids\/14.1.183","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.11.002","article-title":"High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era","volume":"22","author":"Evernden C","year":"2020","unstructured":"Evernden C, Dowhan M, Dabas R, et al.. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era. Cytotherapy. 2020, 22:27-34. 10.1016\/j.jcyt.2019.11.002","journal-title":"Cytotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS, France","volume":"20","author":"Roux A","year":"2014","unstructured":"Roux A, Canet E, Valade S, et al.. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis. 2014, 20:1490-7. 10.3201\/eid2009.131668","journal-title":"Emerg Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-024-04350-4","article-title":"Pneumocystis jirovecii pneumonia: a\u00a0case report","volume":"18","author":"Gri J","year":"2024","unstructured":"Gri J, Jain V. Pneumocystis jirovecii pneumonia: a\u00a0case report. J Med Case Rep. 2024, 18:52. 10.1186\/s13256-024-04350-4","journal-title":"J Med Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248524","article-title":"Efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of pneumocystis pneumonia in human immunodeficiency virus-negative immunodeficient patients: a systematic review and meta-analysis","volume":"16","author":"Li R","year":"2021","unstructured":"Li R, Tang Z, Liu F, Yang M. Efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of pneumocystis pneumonia in human immunodeficiency virus-negative immunodeficient patients: a systematic review and meta-analysis. PLoS One. 2021, 16:10.1371\/journal.pone.0248524","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19052833","article-title":"Trimethoprim-sulfamethoxazole (Bactrim) dose optimization in Pneumocystis jirovecii pneumonia (PCP) management: a systematic review","volume":"19","author":"Haseeb A","year":"2022","unstructured":"Haseeb A, Abourehab MA, Almalki WA, et al.. Trimethoprim-sulfamethoxazole (Bactrim) dose optimization in Pneumocystis jirovecii pneumonia (PCP) management: a systematic review. Int J Environ Res Public Health. 2022, 19:10.3390\/ijerph19052833","journal-title":"Int J Environ Res Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.11.017","article-title":"Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: a case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation","volume":"30","author":"Robin C","year":"2024","unstructured":"Robin C, Cordonnier C, Tridello G, et al.. Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: a case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2024, 30:235.e1-10. 10.1016\/j.jtct.2023.11.017","journal-title":"Transplant Cell Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jof9040406","article-title":"Incidence of pneumocystis pneumonia in immunocompromised patients without human immunodeficiency virus on intravenous pentamidine prophylaxis: a systematic review and meta-analysis","volume":"9","author":"Chiu CY","year":"2023","unstructured":"Chiu CY, Ching PR. Incidence of pneumocystis pneumonia in immunocompromised patients without human immunodeficiency virus on intravenous pentamidine prophylaxis: a systematic review and meta-analysis. J Fungi (Basel). 2023, 9:10.3390\/jof9040406","journal-title":"J Fungi (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.04.011","article-title":"Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study","volume":"11","author":"Sangiolo D","year":"2005","unstructured":"Sangiolo D, Storer B, Nash R, et al.. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant. 2005, 11:521-9. 10.1016\/j.bbmt.2005.04.011","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S406904","article-title":"A case of severe pneumocystis pneumonia in an HIV-negative patient successfully treated with oral atovaquone","volume":"16","author":"Hirai J","year":"2023","unstructured":"Hirai J, Mori N, Kato H, Asai N, Hagihara M, Mikamo H. A case of severe pneumocystis pneumonia in an HIV-negative patient successfully treated with oral atovaquone. Infect Drug Resist. 2023, 16:1561-6. 10.2147\/IDR.S406904","journal-title":"Infect Drug Resist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/258985-breakthrough-pneumocystis-jirovecii-pneumonia-in-an-allogeneic-hematopoietic-stem-cell-transplant-recipient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T14:12:49Z","timestamp":1717769569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/258985-breakthrough-pneumocystis-jirovecii-pneumonia-in-an-allogeneic-hematopoietic-stem-cell-transplant-recipient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.61890","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}